Home Health Medtronic Announces Scientific Data Presentations at the 14th International Conference on Advanced Technologies & Treatments for Diabetes

Medtronic Announces Scientific Data Presentations at the 14th International Conference on Advanced Technologies & Treatments for Diabetes

Data on the Company's Holistic Portfolio Will Include Real-World Data on MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set

by PrittlePrattleNews

DUBLIN, June 1, 2021 – Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced its virtual participation at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place June 2-5, 2021.

Medtronic will showcase clinically meaningful outcomes associated with the company’s comprehensive product portfolio and future technologies and customer-centric support and services provided in a remote environment during the COVID-19 pandemic, including onboarding and training for healthcare providers and patients.

Scientific Presentation: The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing to query presenters throughout the conference.

About the Diabetes Business at the company: 

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care, and improving outcomes, allowing people living with diabetes to enjoy greater freedom and better health.

About the company: Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s most influential medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in 150 countries. The company is focused on collaborating with stakeholders worldwide to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 


Cutting-edge healthcare technology solutions are available for the most complex and challenging circumstances, inspiring people worldwide with optimism and new possibilities.
Medtronic plc is a medical device firm based in the United States owned by an American-Irish partnership. Medtronic’s operations and executive headquarters are located in Minneapolis, Minnesota. In history’s most extensive U.S. business tax inversion, They bought Irish–tax registered Covidien (a U.S. tax inversion to Ireland from 2007), allowing them to relocate its legal registration from the United States to Ireland. Medtronic employs more than 104,950 employees in 140 countries.
Earl Bakken and his brother-in-law, Palmer Hermundslie, launched Medtronic as a medical equipment repair firm in Minneapolis in 1949.
Through his repair business, Bakken met C. Walton Lillehei, a cardiac surgeon at the University of Minnesota Medical School. Following a power outage that struck vast portions of Minnesota and western Wisconsin on Halloween in 1957, the flaws in artificial pacemakers were painfully apparent.  Lillehei’s pacemaker-dependent pediatric patient died as a result of the blackout. Lillehei met with Bakken the next day to discuss constructing a battery-powered pacemaker. Bakken built the first battery-powered external pacemaker by modifying the design of a transistorized metronome.
Throughout the 1950s, the company grew, selling equipment created by others while also manufacturing custom-made products. Bakken devised a battery-powered pacemaker that could be worn to the body. In 1960, research in this new sector resulted in developing an implanted pacemaker. In 1960, the company established its headquarters in St. Anthony, Minnesota, a Minneapolis suburb, and then in the 1970s, it relocated to Fridley. Boston Scientific and St. Jude Medical are two of Medtronic’s primary competitors in the cardiac rhythm industry.
Medtronic established a manufacturing facility for implantable pacemakers and brain pacemakers in Tolochenaz, Switzerland, in 1997. One out of every five pacemakers implanted today is made in the United States. The location also serves as a European medical training center. The company purchased Physio-Control for $538 million in 1998.
Integra Lifesciences stated in 2014 that it would buy the comany’s instrumentation lines for $60 million. MicroFrance and Xomed manual ENT and laparoscopic surgical equipment and a production plant in France were included in the acquisition.

This article is shared with Prittle Prattle News in the form of a Press Release.rt

You may also like

Our Company

Prittle Prattle News also known as PP News, is an internationally most reliable business online news portal – prittleprattlenews is among trusted, respected, and fastest-growing online news portals. 

@2021 – All Right Reserved. Designed and Developed by Prittle Prattle